The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.

The large molecule drug substance CDMO market is anticipated to expand at a CAGR of ~9% during the forecast period. Key ...

Patent settlements accelerate the entry of generics and biosimilars, saving the health care system $422.9 billion and ...

Discover trends shaping the pharmaceutical sector. Get insights on rising prescription drug prices, supply chains, and growth ...

We previously reported on an uptick in the passage of state drug price transparency legislation. What follows is an update to that report. As of ...

Alvotech is expanding its partnership with Advanz Pharma to commercialize new products in Europe, including a Kesimpta ...

Samsung Bioepis and Organon shared that the Food and Drug Administration has designated the Hadlima (adalimumab-bwwd) high- ...

Most-favored-nation pricing is “founded on incorrect assumptions about where high out-of-pocket costs really come from and what it would mean for the US to adopt cost-effectiveness standards used by ...

Crisil Ratings reports that President Trump's order to cut US drug prices will have a limited effect on Indian pharma.

Citing the reason behind its observation, the credit rating firm in its report said that despite India exporting over half of ...

Oncology biosimilars significantly reduce financial toxicity in cancer care, as highlighted in 2 abstracts presented at the ...

The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Starjemza, ...